...
首页> 外文期刊>Biopharmaceutics and Drug Disposition >Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions.
【24h】

Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions.

机译:酮康唑和利福平对OAT1和OATP1B1转运活性的抑制作用:对药物相互作用的考虑。

获取原文
获取原文并翻译 | 示例

摘要

Ketoconazole and rifampin are the most widely used compounds examined in recent drug-drug interaction (DDI) studies, and they have multiple roles in modulating drug metabolizing enzymes and transporters. To determine the underlying mechanisms of DDI, this study was performed to investigate the inhibitory effects of ketoconazole and rifampin on the functions of OAT1 and OATP1B1, and to evaluate the potential of ketoconazole and rifampin for DDI with substrate drugs for these transporters in a clinical setting. Ketoconazole inhibited OATP1B1-mediated transport activity, while rifampin inhibited OAT1 and OATP1B1. Inhibition by rifampin and ketoconazole of the uptake of olmesartan, a substrate for OAT1 and OATP1B1, was evaluated in oocytes overexpressing these transporters. The K(i) values for rifampin on OAT1 and OATP1B1-mediated olmesartan uptake were 62.2 and 4.42 microM, respectively, and the K(i) value for ketoconazole on OATP1B1-mediated olmesartan uptake was 66.1 microM. As measured plasma concentrations of rifampin and ketoconazole were 7.29 and 6.4-13.3 microM, respectively, the likelihood of an OATP1B1-mediated drug-drug interaction between rifampin and olmesartan is thought to be possible, whereas OAT1 or OATP1B1-mediated DDI between rifampin or ketoconazole and olmesartan appears unlikely in the clinical setting.
机译:酮康唑和利福平是最近药物-药物相互作用(DDI)研究中使用最广泛的化合物,它们在调节药物代谢酶和转运蛋白中具有多种作用。为了确定DDI的潜在机制,本研究旨在研究酮康唑和利福平对OAT1和OATP1B1功能的抑制作用,并评估酮康唑和利福平与底物药物在DDI的临床应用中对DDI的潜力。 。酮康唑抑制OATP1B1介导的转运活性,而利福平则抑制OAT1和OATP1B1。在过表达这些转运蛋白的卵母细胞中,评估了利福平和酮康唑对奥美沙坦(OAT1和OATP1B1的底物)摄取的抑制作用。利福平对OAT1和OATP1B1介导的奥美沙坦摄取的K(i)值分别为62.2和4.42 microM,酮康唑对OATP1B1介导的奥美沙坦摄取的K(i)值为66.1 microM。由于测得的利福平和酮康唑的血浆浓度分别为7.29和6.4-13.3 microM,利福平和奥美沙坦之间可能存在OATP1B1介导的药物相互作用的可能性,而利福平或酮康唑之间可能存在OAT1或OATP1B1介导的DDI。奥美沙坦在临床上不太可能出现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号